Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Hepatology

• Publication date

  2015-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.28155PMID 26361374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NK cells regulating T cell responses: mechanisms and outcome.

  2015cited by this paper
• The Role of Natural Killer Cells and CD8+ T Cells in Hepatitis B Virus Infection

  2014cited by this paper
• Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

  2014cited by this paper
• Compromised function of natural killer cells in acute and chronic viral hepatitis.

  2014cited by this paper
• Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?

  2014cited by this paper
• Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection

  2013cited by this paper
• NK Cells: A Double-Edged Sword in Chronic Hepatitis B Virus Infection

  2013cited by this paper
• Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

  2013cited by this paper
• Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion

  2013cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

  2012influential reference
• Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?

  2012cited by this paper
• Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.

  2011cited by this paper
• Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity

  2011cited by this paper
• Innate or Adaptive Immunity? The Example of Natural Killer Cells

  2011cited by this paper
• Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

  2011cited by this paper
• Natural killer cells act as rheostats modulating antiviral T cells

  2011cited by this paper
• Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection

  2010cited by this paper
• Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.

  2009cited by this paper
• Scalable analysis of flow cytometry data using R/Bioconductor

  2009cited by this paper
• Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage

  2007cited by this paper

• Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

  2025cites this paper
• Ultrasoft hydrogel immune millirobot with multimodal locomotion

  2025cites this paper
• Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice.

  2025cites this paper
• Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection

  2025cites this paper
• The role of immune regulation in HBV infection and hepatocellular carcinogenesis

  2025cites this paper
• Harnessing CD8+ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions

  2024cites this paper
• HBV Biomarkers and Their Role in Guiding Treatment Decisions

  2024cites this paper
• Immune Response to Occult Hepatitis B Virus Infection Among Hemodialysis Patients: a review

  2024cites this paper
• A comprehensive model to better screen out antiviral treatment candidates for chronic hepatitis B patients.

  2024cites this paper
• Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B

  2024cites this paper
• Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies

  2023cites this paper
• Characteristics of circulating immune cells in HBV-related acute-on-chronic liver failure following artificial liver treatment

  2023cites this paper
• What Is the Current Status of Hepatitis B Virus Viro-Immunology?

  2023cites this paper
• The scientific basis of combination therapy for chronic hepatitis B functional cure

  2023cites this paper
• Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine

  2022cites this paper
• Increased ILT2 expression contributes to dysfunction of CD56dimCD16+NK cells in chronic hepatitis B virus infection.

  2022cites this paper
• NK cells limit therapeutic vaccine–induced CD8+T cell immunity in a PD-L1–dependent manner

  2022cites this paper
• Innate and adaptive immune escape mechanisms of hepatitis B virus

  2022cites this paper
• Single MHC‐I Expression Promotes Virus‐Induced Liver Immunopathology

  2022cites this paper
• Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients

  2022cites this paper
• Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression

  2021cites this paper
• The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection

  2021cites this paper
• Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma

  2021cites this paper
• Peg‐interferon alpha add‐on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg‐positive chronic hepatitis B naïve patients

  2021cites this paper
• Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-naïve chronic hepatitis B patients

  2021cites this paper
• Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis

  2020cites this paper
• LAG3 is a Central Regulator of NK Cell Cytokine Production

  2020cites this paper
• The Effects of Nucleoside/Nucleotide Analogues on Host Immune Cells: The Baseline for Future Immune Therapy for HBV?

  2020cites this paper
• Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection

  2020cites this paper
• Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches

  2020cites this paper
• Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB

  2020cites this paper
• Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

  2020cites this paper
• Metabolic regulation of the HBV-specific T cell function.

  2020cites this paper
• Reversal of Immunity After Clearance of Chronic HCV Infection—All Reset?

  2020cites this paper
• HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications

  2019cites this paper
• Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

  2019cites this paper
• Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

  2019cites this paper
• Hepatitis B: Prognosis and Treatment

  2019cites this paper
• NKG2A is a NK cell exhaustion checkpoint for HCV persistence

  2019cites this paper
• [Efficacy and peripheral immunity analysis of allogeneic natural killer cells therapy in patients with hepatocellular carcinoma].

  2019cites this paper
• Restoring, releasing or replacing adaptive immunity in chronic hepatitis B

  2019cites this paper
• The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy

  2019cites this paper
• Liver-Mediated Adaptive Immune Tolerance

  2019cites this paper
• Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B

  2019cites this paper
• Unconventional T cells in chronic hepatitis B patients on long‐term suppressive therapy with tenofovir followed by a Peg‐IFN add‐on strategy: A randomized study

  2018cites this paper
• Effect of Pegylated Interferon Add-On Therapy to Achieve Disease Remission in Patients with Chronic Hepatitis B

  2018cites this paper
• Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

  2018cites this paper
• Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

  2018cites this paper
• Perspectives and limitations for nucleo(t)side analogs in future HBV therapies.

  2018cites this paper
• Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss

  2018cites this paper
• TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

  2018cites this paper
• Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications

  2018cites this paper
• The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics

  2018cites this paper
• NK cells in liver disease

  2018influential citation
• Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection

  2018cites this paper
• Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease

  2018cites this paper
• Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand.

  2018cites this paper
• Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming.

  2018cites this paper
• Mechanisms behind TB, HBV, and HIV chronic infections.

  2017cites this paper
• Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)

  2017cites this paper
• Chronic hepatitis B surface antigen seroclearance‐related immune factors

  2017cites this paper
• Natural Killer Cells in Hepatocellular Carcinoma: Anti-Tumor Effect and Therapeutic Potential

  2017cites this paper
• Natural Killer Cells in Liver Disease

  2017cites this paper
• A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection

  2017cites this paper
• NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection

  2017cites this paper
• Circulating NK cells and their subsets in Behçet's disease

  2017cites this paper
• T cell regulation in HBV-related chronic liver disease.

  2017cites this paper
• Understanding the Innate Immune Response in Viral Hepatitis : Interferons and NK Cells

  2017cites this paper
• Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver

  2017cites this paper
• Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B

  2017cites this paper
• Adaptive immunity in HBV infection.

  2016cites this paper
• The role of innate immunity in the immunopathology and treatment of HBV infection.

  2016cites this paper
• Recognition and Regulation of T Cells by NK Cells

  2016cites this paper
• Hepatitis B: treatment choice and monitoring for response and resistance

  2016cites this paper
• Exosomes: multitask cargo carriers modulating innate immunity to viruses

  2016cites this paper
• Host–virus interactions in hepatitis B and hepatitis C infection

  2016cites this paper
• Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics.

  2016cites this paper
• Immune responses and immunopathology in acute and chronic viral hepatitis

  2016cites this paper
• Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.

  2016cites this paper
• HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.

  2016cites this paper
• T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System

  2016cites this paper
• Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo

  2016cites this paper
• NKG2D-DEPENDENT CROSS-TALK BETWEEN NK CELLS AND CD4 T CELLS IN CHRONIC HEPATITIS B

  2015influential citation